• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»YASHRAJ BIOTECHNOLOGY LIMITED (YBL) 20 YEARS OF EXCELLENCE IN TRANSFORMING WASTE TO WELL-BEING

YASHRAJ BIOTECHNOLOGY LIMITED (YBL) 20 YEARS OF EXCELLENCE IN TRANSFORMING WASTE TO WELL-BEING

0
By Biotech Express on February 6, 2019 Articles, Articles- Guestorials

Introduction

Progress is not about how we grow, it is about how we make a difference in lives of others! This is the guiding principle at Yashraj Biotechnology Limited (YBL), a pioneering biotechnology company located in Navi Mumbai, India. The founder members of the company Mr. Arvind Bhanushali, Mr. Bharat Dagha and Dr. Paresh Bhanushali started the company in 1999 and this year the company is celebrating its 20 years of
existence.

The company was established with a vision to be the best in the diagnostic field and make diagnostics
affordable and easily available to the common man. Today, YBL is a leading name in the in vitro diagnostic market, supplying high purity Antigens, Antibodies, proteins and enzymes to some of the world’s top 20
diagnostic companies.

From Bio-Medical Waste to Diagnostic Application Products: An Innovative Approach

YBL capitalizes on usefulness of the human biomedical waste generated by the hospitals for diagnostic
purposes by manufacturing Native Antigens (Table 1) which are purified from the effusions of patients
suffering from cancer, renal, and cardiac failures. In addition to diagnostic use, the manufacturing processes at YBL indirectly helps in reducing the environmental pollution due to disposal of human biomedical waste which is a major concern to the hospitals, the regulatory authorities and the citizens.

The Biomedical waste management teams at YBL have created a Pan India network to access Bio-medical fluids for extraction and purification of high quality Native and Recombinant Antigens in a time-effective manner.

State-of-the-Art Research & Development

YBL has a well-equipped Research & Development (R&D) unit in which a wide range of high-quality Antigens (Native and Recombinant), Proteins, Enzymes are manufactured using advanced chromatography systems like AKTA prime plus and AKTA Pure for protein purification.

The Recombinant R&D facility manufactures highly purified proteins and enzymes both with and without tags and by using different expression systems like Bacterial (E. coli), Mammalian (CHO, HeLa, HEK293, MCF7), Bacculovirus (Spodoptera frugiperda) Sf9/Sf21 insect cells and Yeast (Saccharomyces cerevisiae).

Highly specific and high affinity monoclonal and polyclonal Antibodies are developed and characterized by Surface Plasma Resonance (SPR) using Biacore T200 system. These Antibodies are validated by external agencies and certified for use in development of immunoassays like Enzyme-linked Immuno Sorbent Assay (ELISA), Flow Cytometry, Chemiluminescence Assays (CLIA) and Immunohistochemistry (IHC).

YBL products basket contains more than 25 Native and 22 Recombinant Antigens with a purity percentage ranging from 90-99% (To download YBL products booklet please write to marketing@yashrajbio.com).

Efficient Production and Rigorous Quality Checks
A seamless transition occurs between the R&D and the production unit for scaling up and mass production of protein. Standard operating procedures are followed to maintain batch to batch consistencies irrespective of capacity (from small to bulk production). The emphasis lies on the maintenance of long-term stability, specificity and purity of the products which is ensured by Quality Control. Rigorous testings are performed on multiple platforms like Roche Cobas e411 & c311 and Siemens Advia Centaur CP & XP analyzers.

Protein quantification and validation is done using ELISA, ECLIA, Immunonephelometry, Immunoturbidimetry and Latex Agglutination, SDS-PAGE, Western Blotting, HPLC, Crossed immunoelectrophoresis (CIE) and Mass-Spectrometry. Real and accelerated stability tests are performed for batch consistency and viral contamination is identified by performing PCR and USFDA approved CLIA techniques. Once the protein quality is confirmed and certified, they are properly labeled and packaged for a timely delivery to the customers worldwide.

Stem Cell & Antibody Phage Display: New Ventures
In the last 2 years, YBL is diversifying its R&D activities to develop IPSCs Stem Cell technology for drug discovery and screening. It has successfully developed methodologies to bio-bank peripheral blood mononuclear cells and erythroblast cell populations from cancer patients and healthy individuals (controls).

In 2018, YBL ventured into production of Recombinant Monoclonal Antibodies using Phage Display for Diagnostic & Research purpose. Currently, both the facilities are in initial stages of development and the products are expected to be available in the market by July 2020.

CSR at YBL: Grants and Awards Sponsorship
Every year YBL donates a percentage of the profit for Corporate Social Responsibility (CSR) initiatives like Healthcare and Education for the welfare of economically weaker section of the society. The amount depends on the profit generated and is decided by the Board. For more details please see http://yashraj.com/csr/

The YBL company’s major activities involve:

Isolation, purification and production of Native and Recombinant proteins;

Development of polyclonal and monoclonal Antibodies against
Immunogens;

Production of cell-derived Native Antigens using appropriate cell lines.

Moreover, YBL in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) sponsors the IFCC-Yashraj Biotechnology Limited Distinguished Clinical Chemist Award & IFCC-Yashraj Biotechnology Limited Distinguished Award for Contributions to Affordable In vitro Diagnostics to recognize researchers who have made significant contributions in this discipline.

Come and join us at Yashraj Biotechnology Limited in our quest to make diagnostics more affordable and accessible!

For any query please write to marketing@yashrajbio.com

Website: www.yashraj.com

Linkedin: linkedin.com/company/yashraj-biotechnology-ltd

Twitter handle: @YashrajBio

Facebook: Yashraj Biotechnology Ltd

Certifications:: ISO 9001: 2015 and ISO 13485: 2016

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha

Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.